Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas

Virchows Archiv

Volumn 464, Issue 5, 2014, Pages 603-612

  Kiszner, Gergo ^a   Wichmann, Barnabas ^a   Nemeth, Istvan B ^b   Varga, Erika ^b   Meggyeshazi, Nora ^a   Teleki, Ivett ^a   Balla, Peter ^a   Maros, Mate E ^a   Penksza, Karoly ^c   Krenacs, Tibor ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c SZENT ISTVÁN UNIVERSITY   (Hungary)

Author keywords

Cell cycle phase analysis; Cutaneous melanoma; Ki67; Mcm6; Post G1 phase markers

Indexed keywords

AURORA A KINASE; AURORA B KINASE; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GEMININ; MINICHROMOSOME MAINTENANCE PROTEIN 6;

ADULT; ANTIGEN DETECTION; ANTIGEN RETRIEVAL; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS MELANOMA; DYSPLASTIC NEVUS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MELANOCYTE; MELANOMA; METASTATIC MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN METASTASIS; TISSUE MICROARRAY;

ADOLESCENT; ADULT; CELL CYCLE; CELL CYCLE PROTEINS; CHILD; DIAGNOSIS, DIFFERENTIAL; DYSPLASTIC NEVUS SYNDROME; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84902319384     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1570-1     Document Type: Article

References (59)

1. Garbe C, Leiter U (2009) Melanoma epidemiology and trends. Clin Dermatol 27:3-9. doi:10.1016/j.clindermatol.2008.09.001
2. Leiter U, Meier F, Schittek B, Garbe C (2004) The natural course of cutaneous melanoma. J Surg Oncol 86:172-178. doi:10.1002/jso.20079 (Pubitemid 38880283)
3. Stratigos AJ, Katsambas AD (2009) The value of screening in melanoma. Clin Dermatol 27:10-25. doi:10.1016/j.clindermatol.2008.09.002
4. Duffy K, Grossman D (2012) The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management. J Am Acad Dermatol 67(19):e11-e12
5. Rabkin MS (2008) The limited specificity of histological examination in the diagnosis of dysplastic nevi. J Cutan Pathol 35(Suppl 2):20-23. doi:10.1111/j.1600-0560.2008.01131.x
6. Carlson JA, Ross JS, Slominski A, Linette G, Mysliborski J, Hill J, Mihm M Jr (2005) Molecular diagnostics in melanoma. J Am Acad Dermatol 52:743-775. doi:10.1016/j.jaad.2004.08.034, quiz 775-748
7. Sekulic A, Haluska P Jr, Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, Salomao DR, Thorland EC, Vile RG, SwansonDL, Pockaj BA, Laman SD, Pittelkow MR, Markovic SN (2008) Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc 83:825-846 (Pubitemid 351948695)
8. Williams GH, Stoeber K (2012) The cell cycle and cancer. J Pathol 226:352-364. doi:10.1002/path.3022
9. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS (2003) High frequency of BRAF mutations in nevi. Nat Genet 33:19-20. doi:10.1038/ng1054 (Pubitemid 36068675)
10. Lei M (2005) The MCM complex: its role in DNA replication and implications for cancer therapy. Curr Cancer Drug Targets 5:365-380
11. Vermeulen K, Van Bockstaele DR, Berneman ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36:131-149 (Pubitemid 36808270)
12. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73:39-85. doi:10.1146/annurev.biochem.73.011303.073723 (Pubitemid 39050363)
13. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P (2002) Culprit and victim-DNA topoisomerase. II Lancet Oncol 3:235-243
14. Diffley JF (2004) Regulation of early events in chromosome replication. Curr Biol 14:R778-R786. doi:10.1016/j.cub.2004.09.019
15. Vader G, Lens SM (2008) The aurora kinase family in cell division and cancer. BiochimBiophysActa 1786:60-72. doi:10.1016/j.bbcan.2008.07.003
16. Brown DC, Gatter KC (2002) Ki67 protein: the immaculate deception? Histopathology 40:2-11 (Pubitemid 34107377)
17. Endl E, Gerdes J (2000) The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 257:231-237. doi:10.1006/excr.2000.4888 (Pubitemid 30390473)
18. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674. doi:10.1016/j.cell.2011.02.013
19. Pierard GE (2012) Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression. ISRN Dermatol 2012:828146. doi:10.5402/2012/828146
20. Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, Pajares R, Martinez-Tello FJ, Hortelano CM, Piris MA, Rodriguez-Peralto JL (2004) Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 164:193-203 (Pubitemid 38364604)
21. Georgieva J, Sinha P, Schadendorf D (2001) Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol 54:229-235 (Pubitemid 32205046)
22. Li W, Sanki A, Karim RZ, Thompson JF, Soon Lee C, Zhuang L, McCarthy SW, Scolyer RA (2006) The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 38:287-301. doi:10.1080/00313020600817951 (Pubitemid 44266625)
23. Quatresooz P, Pierard GE, Pierard-Franchimont C (2009) Molecular pathways supporting the proliferation staging of malignant melanoma (review). Int J Mol Med 24:295-301
24. Moore MW, Gasparini R (2011) FISH as an effective diagnostic tool for themanagement of challengingmelanocytic lesions. Diagn Pathol 6:76. doi:10.1186/1746-1596-6-76
25. Vergier B, Prochazkova-Carlotti M, de la Fouchardiere A, Cerroni L, Massi D, De Giorgi V, Bailly C, Wesselmann U, Karlseladze A, Avril MF, Jouary T, Merlio JP (2011) Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases. Mod Pathol 24:613-623. doi:10.1038/modpathol.2010.228
26. Zhang G, Li G (2012) Novel multiple markers to distinguish melanoma from dysplastic nevi. PLoS One 7:e45037. doi:10.1371/journal.pone.0045037
27. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol : Off J Am Soc Clin Oncol 27:6199-6206. doi:10.1200/jco.2009.23.4799
28. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847 (Pubitemid 28331029)
29. Krenacs T, Ficsor L, Varga SV, Angeli V, Molnar B (2010) Digital microscopy for boosting database integration and analysis in TMA studies. Methods Mol Biol 664:163 - 175. doi:10.1007/978-1-60761-806-5-16
30. Krenacs T, KisznerG, Stelkovics E, Balla P, Teleki I, Nemeth I, Varga E, Korom I, Barbai T, Plotar V, Timar J, Raso E (2012) Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis. Histochem Cell Biol 138:653-667. doi:10.1007/s00418-012-0981-9
31. McLachlan GJ (2005) General introduction. Discriminant analysis and statistical pattern recognition. Wiley, pp. 1-26
32. McLachlan GJ (2005) Likelihood-based approaches to discrimination. Discriminant analysis and statistical pattern recognition. Wiley, pp. 27-51
33. Salopek TG, Kopf AW, Stefanato CM, Vossaert K, Silverman M, Yadav S (2001) Differentiation of atypical moles (dysplastic nevi) from early melanomas by dermoscopy. Dermatol Clin 19:337-345 (Pubitemid 32807771)
34. Troxel DB (2003) Pitfalls in the diagnosis of malignant melanoma: findings of a risk management panel study. Am J Surg Pathol 27:1278-1283
35. Hussein MR, Sun M, Tuthill RJ, Roggero E, Monti JA, Sudilovsky EC, Wood GS, Sudilovsky O (2001) Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. J Cutan Pathol 28:343-350 (Pubitemid 32667004)
36. van den Hurk K, Niessen HE, Veeck J, van den Oord JJ, van Steensel MA, Zur Hausen A, van Engeland M, Winnepenninckx VJ (2012) Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. Biochim Biophys Acta 1826:89-102. doi:10.1016/j.bbcan.2012.03.011
37. Kuzbicki L, Aladowicz E, Chwirot BW (2006) Cyclin-dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions. Melanoma Res 16:435 - 444. doi:10.1097/01.cmr.0000232290.61042.ee
38. Alekseenko A, Wojas-Pelc A, Lis GJ, Furgal-Borzych A, Surowka G, Litwin JA (2010) Cyclin D1 and D3 expression in melanocytic skin lesions. Arch Dermatol Res 302:545-550. doi:10.1007/s00403-010-1054-3
39. de Sa BC, Fugimori ML, Ribeiro Kde C, Duprat Neto JP, Neves RI, Landman G (2009) Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas. Melanoma Res 19:135-141. doi:10.1097/CMR.0b013e32831993f3
40. Karim RZ, Li W, Sanki A, Colman MH, Yang YH, Thompson JF, Scolyer RA (2009) Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors. Int J Surg Pathol 17:361-367. doi:10.1177/1066896909336177
41. Ramirez JA, Guitart J, Rao MS, Diaz LK (2005) Cyclin D1 expression inmelanocytic lesions of the skin. AnnDiagn Pathol 9:185-188. doi:10.1016/j.anndiagpath.2005.04.018 (Pubitemid 41111827)
42. Bales ES, Dietrich C, Bandyopadhyay D, Schwahn DJ, Xu W, Didenko V, Leiss P, Conrad N, Pereira-Smith O, Orengo I, Medrano EE (1999) High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol 113:1039-1046. doi:10.1046/j.1523-1747.1999.00812.x (Pubitemid 30013350)
43. Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R (2001) Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol 195:530-536. doi:10.1002/path.1007 (Pubitemid 34030789)
44. Tran TA, Ross JS, Carlson JA, Mihm MC Jr (1998) Mitotic cyclins and cyclin-dependent kinases inmelanocytic lesions. Hum Pathol 29:1085-1090 (Pubitemid 28467528)
45. Stefanaki C, Stefanaki K, Antoniou C, Argyrakos T, Patereli A, Stratigos A, Katsambas A (2007) Cell cycle and apoptosis regulators in Spitz nevi: comparison with melanomas and common nevi. J Am Acad Dermatol 56:815-824. doi:10.1016/j.jaad.2006.09.015 (Pubitemid 46560996)
46. Boyd AS, Shakhtour B, Shyr Y (2008) Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases. J Am Acad Dermatol 58:750-754. doi:10.1016/j.jaad.2007.12.026
47. de Andrade BA, Leon JE, Carlos R, Delgado-Azanero W, Mosqueda-Taylor A, de Almeida OP (2013) Expression of minichromosome maintenance 2, Ki-67, and geminin in oral nevi and melanoma. Ann Diagn Pathol 17:32-36. doi:10.1016/j.anndiagpath.2012.05.001
48. Gambichler T, Shtern M, Rotterdam S, Bechara FG, Stucker M, Altmeyer P, Kreuter A (2009) Minichromosome maintenance proteins are useful adjuncts to differentiate between benign and malignant melanocytic skin lesions. J Am Acad Dermatol 60:808-813. doi:10.1016/j.jaad.2009.01.028
49. Lynch BJ, Komaromy-Hiller G, Bronstein IB, Holden JA (1998) Expression of DNA topoisomerase I, DNA topoisomerase IIalpha, and p53 in metastatic malignant melanoma. Hum Pathol 29:1240 -1245
50. Mu XC, Tran TA, Ross JS, Carlson JA (2000) Topoisomerase IIalpha expression in melanocytic nevi and malignant melanoma. J Cutan Pathol 27:242-248 (Pubitemid 30248967)
51. Wang X, Moschos SJ, Becker D (2010) Functional analysis and molecular targeting of aurora kinases A and B in advanced melanoma. Genes Cancer 1:952-963. doi:10.1177/1947601910388936
52. Bergman R, Malkin L, Sabo E, Kerner H (2001) MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. J Am Acad Dermatol 44:500-504. doi:10.1067/mjd.2001.111635 (Pubitemid 32199972)
53. Chorny JA, Barr RJ, Kyshtoobayeva A, Jakowatz J, Reed RJ (2003) Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions. Mod Pathol 16:525-529. doi:10.1097/01.mp.0000072747. 08404.38 (Pubitemid 36718432)
54. Kaleem Z, Lind AC, Humphrey PA, Sueper RH, Swanson PE, Ritter JH, Wick MR (2000) Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?Mod Pathol 13:217-222. doi:10.1038/modpathol.3880040 (Pubitemid 30207505)
55. Kapur P, Selim MA, Roy LC, Yegappan M, Weinberg AG, Hoang MP(2005) Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. Mod Pathol 18:197-204. doi:10.1038/modpathol.3800281 (Pubitemid 40188626)
56. Scatolini M, Grand MM, Grosso E, Venesio T, Pisacane A, Balsamo A, Sirovich R, Risio M, Chiorino G (2010) Altered molecular pathways in melanocytic lesions International journal of cancer. J Int du Cancer 126:1869-1881. doi:10.1002/ijc.24899
57. Loddo M, Kingsbury SR, Rashid M, Proctor I, Holt C, Young J, El-Sheikh S, Falzon M, Eward KL, Prevost T, Sainsbury R, Stoeber K, Williams GH (2009) Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer 100:959-970. doi:10.1038/sj.bjc.6604924
58. Vizkeleti L, Ecsedi S, Rakosy Z, Orosz A, Lazar V, EmriG, Koroknai V, Kiss T, Adany R, BalazsM(2012) The role of CCND1 alterations during the progression of cutaneous malignant melanoma. Tumour Biol 33:2189-2199. doi:10.1007/s13277-012-0480-6
59. Hoek KS, Eichhoff OM, Schlegel NC, Dobbeling U, Kobert N, Schaerer L, Hemmi S, Dummer R (2008) In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 68:650-656. doi:10.1158/0008-5472. can-07-2491 (Pubitemid 351206739)